Holen Sie sich die Stockscreener-App
1.19
4.39%
0.05
Handel nachbörslich:
1.19
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Pliant Therapeutics (PLRX) director receives 70,000 stock options at $1.14 - Stock Titan
Pliant Therapeutics (PLRX) director granted 70,000 options at $1.14 strike - Stock Titan
Pliant Therapeutics (PLRX) director receives 70,000-share stock option grant - Stock Titan
Pliant (NASDAQ: PLRX) director awarded 70,000 stock options at $1.14 - Stock Titan
PLIANT THERAPEUTICS (PLRX) director granted 70,000 stock options at $1.14 - Stock Titan
Director Darren Cline receives 70,000 PLRX stock options at $1.14 strike price - Stock Titan
Pliant Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Pliant Therapeutics (NASDAQ: PLRX) reports 2026 director, pay and auditor votes - Stock Titan
PLIANT THERAPEUTICS INC (PLRX) Stock Chart - ChartMill
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - The Manila Times
Primary Sclerosing Cholangitis Market is Projected to Boom by 2034 Owing to the Launch of Novel Therapies | DelveInsight - Barchart
Pliant Therapeutics (PLRX) Inches Higher: Consolidation Near Support Amid Biotech Sector VolatilityAccumulation Line - newsline.com
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest Gains, Biotech Sector Weakness PersistsNAAIM Leverage - The Legal Advocate
Pliant Therapeutics Rises $1.25 Ahead of ASCO Conference - Bez Kabli
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest Gains – Key Levels in FocusCumulative Volume - The Legal Advocate
Pliant Therapeutics (PLRX) Edges Higher as Stock Holds Above Key SupportNHNL Ratio - The Legal Advocate
Pliant Therapeutics (PLRX) Faces Selling Pressure, Testing Key Support at $1.15Revenue Growth Stocks - newsline.com
Pliant Therapeutics to present Phase 1b trial data of PLN-101095 at ASCO 2026. - Pluang
Pliant Therapeutics (PLRX) Bounces 2.5% as Biotech Tests Key ResistanceStock Idea Network - newser.com
Global oncology researchers to review FORTIFY data as Pliant Therapeutics joins ASCO meeting - Traders Union
Pliant Drug Aims to Break Cancer's Resistance to Immunotherapy - BriefGlance
Pliant Therapeutics (PLRX) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.32Crowd Entry Signals - newser.com
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical ... - Caledonian Record
Pliant Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
Phase 1 cancer trial pairs oral integrin inhibitor with pembrolizumab - Stock Titan
Pliant Therapeutics (PLRX) Stock: Consolidating at $1.20 — Next Move Ahead 2026-05-21Equity Put Call - Newser
Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Pliant Therapeutics (PLRX) Delivers Q1 2026 Beat — EPS $-0.32 vs $-0.36 ExpectedEPS Guidance Update - The Legal Advocate
Australian biotech advancing pulmonary program adds Pliant CEO as chair - Stock Titan
Pliant Therapeutics (PLRX) Stock Price, Quote, Charts & News - Invezz
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board – Company AnnouncementFT.com - Financial Times
TradingKey - TradingKey
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail
Number of shareholders of Pliant Therapeutics, Inc. – MUN:9PT - TradingView
CCORF Downgrades Pliant Therapeutics(PLRX.US) to Hold Rating, Maintains Target Price $3 - Moomoo
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $2 to $3 - Moomoo
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - markets.businessinsider.com
Pliant Therapeutics (PLRX) Advances Clinical Trials and Pipeline Development - GuruFocus
Pliant Therapeutics Q1 net loss narrows on lower expenses - TradingView
Pliant Therapeutics (NASDAQ: PLRX) cuts Q1 2026 net loss to $20M - Stock Titan
Pliant Therapeutics (PLRX) narrows Q1 2026 loss as PLN-101095 shows early responses - Stock Titan
Cancer pill from Pliant shows responses after checkpoint drugs fail - Stock Titan
Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
PLRX (Pliant Therapeutics) quarterly loss narrower than feared; shares tick up as pipeline hopes support sentiment.Margin Improvement - newser.com
The industry tailwinds powering Pliant Therapeutics (PLRX) growth (Smart Money Flows) 2026-05-08Call Spread Alert - newsline.com
Pliant CEO, CFO to join RBC healthcare fireside chat on May 19 - Stock Titan
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pliant Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen - MarketBeat
Pliant Therapeutics (PLRX) Initiates Key Clinical Trial for Canc - GuruFocus
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - Investing News Network
Pliant Therapeutics begins trial of cancer drug combination By Investing.com - Investing.com South Africa
Pliant Therapeutics begins trial of cancer drug combination - Investing.com
Pliant Therapeutics Announces First Patient Dosed in - GlobeNewswire
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):